​Indaclav

​
COMPOSITION:
Each film-coated tablet contains:
Amoxicillin Trihydrate BP
Eq. Amoxicillin 500 mg
Dilute Potassium Clabunate BP
Eq. to Clavulanic acid 62.5 mg
Excipients Q.S.
Colour: Titanium Dioxide B.P

PHARMACOLOGICAL GROUP:

Indaclav 562.5 is an oral antibacterial combination containing one year synthetic: Amoxicillin is a B-lactamase inhibitor, clavulanate
potassium of clavulanic acid), which has a structure close to the
Penicillins.

Pharmacological Action: Amoxicillin is a semi-synthetic antibiotic
active against many Gram-positive and gram-positive microorganisms
negative. Amoxicillin inhibits cell wall synthesis, thus leading to bacterial lysis. however, amoxicillin is likely to be destroyed by B-lactamases, therefore not by the organisms producing these enzymes. Clavulanic acid is lactamases which has the ability to deactivate a wide range of 8-lactam: in microorga

Resistant to penicillin and cephalosporins good activity against B-lactamase mediating plasmids, frequent formula of amoxicillin and clavulanic acid in Indaclav 562.5, the antibacterial spectrum of amoxicillin to the many normal bacteria. amoxicillin and B-lactams.

 

THERAPEUTIC INDICATIONS: Lower respiratory tract infections, Otitis media, Sinusitis, soft tissue infec, urinary tract infections.INDICATIONS: Indaclav 562.5 is contraindicated to expectations with a history of allergy to contraindicated in patients who have suffered from cholestatic oL jaundice associated with Indaclav 562.5.

​

DOSAGE AND METHOD OF ADMINISTRATION:

Dosage expressed as Amoxicillin:

Tablets- Adults: the usual adult dose is 12 hours.

​

Treatment should generally be continued for 48 to 72 days when the patient becomes asymptomatic or where evidence of eradication bact treatment should not exceed 14 days without examination by a doctor.

 

Renal impairment: Indaclav 562.5 tablets should not be used in moderate-to-severe renal impairment (creatinine clearance 30 m/clavulanic acid are both excreted by the kidneys and serum half-life in patients with renal impairment.

 

No adjustment of the starting dose the interval between doses should be extended according to the degree of insufficiency. The following is proposed for Indaclav 562.5: Mild deficiency: (Creatinine clearance > 30 ml/min). Moderate impairment: one tablet every 12 hours (creatinine clearance 10 to 30 mL/min). Indaclav deficiency 562.5 every 24 hours (creatinine clearance < 10 ml/n decreases serum amoxicillin and clavulanic acid concentrations should be administered at the end of dialysis. Adults with function there are currently insufficient data for a posolo recommendation: caution and monitor liver function at intervals